About Frontier Medicines
Frontier Medicines is a Healthcare company based in San Francisco (United States) founded in 2018 by Roberto Zoncu, Daniel Nomura, and Chris Varma. Bioinformatics platform is developed for drug discovery and chemoproteomics. Frontier Medicines has raised $235.5 million across 3 funding rounds from investors including GLPG, RA Capital and Driehaus. The company has 115 employees. Its chief executive, as recorded, is Chris Varma. Frontier Medicines offers products and services including The Frontierâ„¢ Platform, AutoTACâ„¢ Platform, and Precision Pipeline. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is FRONTIER MEDICINES CORPORATION. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Developer of a bioinformatics platform for drug development and chemoproteomics. The proprietary chemoproteomics platform uses machine learning technology to analyze proteins to identify active binding sites as drug targets to treat diseases. The platform consists of a database of hotspots in proteins, a library of chemically diverse compounds, and a novel approach to protein degradation. It ofefrs a lead program FMC-376, which is a novel dual inhibitor of both active and inactive KRASG12 for non-small cell lung, colorectal, and pancreatic cancers.
- Headquarters San Francisco, United States
- Employees 115
- Founders Roberto Zoncu, Daniel Nomura, Chris Varma
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website frontiermeds.com
- Social LinkedIn X
- Legal Name Frontier Medicines Corporation
- Total Equity Funding$235.5M (USD)
in 3 rounds
- Latest Funding Round$80M (USD), Series C
Feb 2024
- InvestorsGLPG
& 11 more
- Employee Count115
Products & Services of Frontier Medicines
Frontier Medicines offers a comprehensive portfolio of products and services, including The Frontier™ Platform, AutoTAC™ Platform, and Precision Pipeline.
Proprietary system using chemoproteomics and machine learning for medicine development.
Technology for targeted degradation of disease-causing proteins.
Pipeline focused on precision-based medicines for specific patient groups.
Funding Insights of Frontier Medicines
Frontier Medicines has successfully raised a total of $235.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $80 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $235.5M
- Total Rounds 3
- Last Round Series C — $80M
- First Round $67M
(Apr 2019)
- Investors Count 12
All 3 funding rounds of Frontier Medicines with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | $80M | Series C | – | Deerfield, Droia Ventures | |
| Jun 2021 | $88.5M | Series B | – | Woodline Partners, RA Capital Management | |
| Apr 2019 | $67M | Series A | – | Deerfield, Droia |
12 investors in total: 12 institutional.
Investors in Frontier Medicines
Frontier Medicines has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include GLPG, RA Capital and Driehaus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Droia Ventures is focused on investing in drug development companies. | droiaventures.com | Luxembourg, Luxembourg | ||
Venture capital firm focused on multiple sectors | dcvc.com | Palo Alto, United States | ||
Deep Track Capital is engaged in biotechnology investment activities. | deeptrackcapital.com | Greenwich, United States | ||
Droia Ventures is focused on investing in drug development companies. | droia.be | Luxembourg, Luxembourg | ||
Small molecule drugs for immunology and oncology are developed. | 1999 | glpg.com | Mechelen, Belgium | |
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
An equity-strategy focused hedge fund for investment management. | 2018 | woodlinepartners.com | San Francisco, United States | |
Diversified asset management services are provided to investors. | 2007 | arrowmarkpartners.com | Denver, United States |
Investor details for Frontier Medicines
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Frontier Medicines
63 people are tracked at Frontier Medicines (20 in leadership, 18 in board & advisors, 25 in team); the tracked headcount is 115.
| Name | Role | Group |
|---|---|---|
Roberto Zoncu | Co-Founder | Leadership |
Daniel Nomura | Co-Founder | Leadership |
Chris Varma | Co-Founder & CEO | Leadership |
Lata Jayaraman | Senior Vice President And Head, Oncology And Inflammation Research | Leadership |
Johannes Hermann | CTO | Leadership |
Kevin Webster | Chief Scientific Officer | Leadership |
Chetan Sukuru | Senior Director, Head Of Research Informatics | Leadership |
Tiep Le | Director, In Vivo Pharmacology | Leadership |
Yan Wang | Head of Translational Medicine | Leadership |
Karsten Krug | Director - Head Of Bioinformatics | Leadership |
Sylvia M. | Chief of Staff | Leadership |
Anthony Romero | Vp, Head Of Medicinal Chemistry | Leadership |
Robert Everley | Senior Director of Chemical Biology | Leadership |
Laci Stanton | Sr. Director, People And Culture | Leadership |
Alessandra Ianari | Senior Director, Head Of Disease Biology | Leadership |
Elizabeth Admirand | Director, Head Of Compound And Sample Management | Leadership |
Weiru Wang | Executive Director, Protein Sciences and Structural Biology | Leadership |
Heidi Cyr BS, LATG, CMAR | Director Of Facilities And Laboratories Boston/san Francisco | Leadership |
Jay Duffner | Associate Director of Discovery Biology | Leadership |
Barun Bhhatarai | Director | Leadership |
43 more people are available in the full profile.
Complete people profiles for Frontier Medicines
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Frontier Medicines
3 dated milestones of Frontier Medicines across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Frontier Medicines is founded.
- Funding First funding round of $67.0M.
- Funding Latest funding round, Series C, of $80.0M.
Competitors of Frontier Medicines
Frontier Medicines has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Frontier Medicines
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Frontier Medicines
The website of Frontier Medicines (frontiermeds.com) receives about 3.5K visits a month and ranks #6,278,645 among all websites worldwide, #6,509 in Biotechnology and Pharmaceuticals.
- Monthly visits3.5K
▲ 40.1% vs previous month
- Unique visitors1K
per month
- Global rank#6,278,645
among all websites
- Category rank#6,509
Health · Biotechnology and Pharmaceuticals
- Bounce rate34%
- Pages per visit1.9
- Average visit34 sec
- DevicesDesktop 38% · Mobile 62%
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Frontier Medicines (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Frontier Medicines
Complete news archive for Frontier Medicines
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Frontier Medicines
Frontier Medicines was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Frontier Medicines is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Chris Varma is the CEO of Frontier Medicines, as recorded in our data. They have also founded this company.
Frontier Medicines is a funded company, having raised a total of $235.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $67M, raised on Apr 2019.
Frontier Medicines has 115 employees.
Developer of a bioinformatics platform for drug development and chemoproteomics. The proprietary chemoproteomics platform uses machine learning technology to analyze proteins to identify active binding sites as drug targets to treat diseases. The platform consists of a database of hotspots in proteins, a library of chemically diverse compounds, and a novel approach to protein degradation. It ofefrs a lead program FMC-376, which is a novel dual inhibitor of both active and inactive KRASG12 for non-small cell lung, colorectal, and pancreatic cancers.
Frontier Medicines's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
Frontier Medicines offers The Frontierâ„¢ Platform, AutoTACâ„¢ Platform, and Precision Pipeline.
Frontier Medicines has 12 investors. Key investors include GLPG, RA Capital, Driehaus, ArrowMark Partners, and Deerfield.
Frontier Medicines operates through Frontier Medicines Corporation.